Literature DB >> 15077650

Confirming an experimental therapy prior to transfer to humans: what is the ideal?

W Dalton Dietrich1.   

Abstract

As the spinal cord injury (SCI) scientific community moves closer to translating experimental data to the clinic, specific steps should be addressed to improve our chances of success. Some of the steps under discussion include animal modeling, clinically relevant endpoints, compelling evidence for improvements, and safety issues. First, it will be beneficial if exciting data are first replicated before findings are considered clinically relevant. Then major findings must be published in peer-reviewed journals so that the scientific community may scrutinize the data. Finally, continued communication between different research groups throughout the world, as well as between basic scientists and clinicians working in the area of SCI, will enhance our progress in this important research field.

Entities:  

Mesh:

Year:  2003        PMID: 15077650     DOI: 10.1682/jrrd.2003.08.0063

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  3 in total

Review 1.  A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury.

Authors:  Brian K Kwon; Elena B Okon; Eve Tsai; Michael S Beattie; Jacqueline C Bresnahan; David K Magnuson; Paul J Reier; Dana M McTigue; Phillip G Popovich; Andrew R Blight; Martin Oudega; James D Guest; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-10-18       Impact factor: 5.269

Review 2.  Cellular treatments for spinal cord injury: the time is right for clinical trials.

Authors:  Michael G Fehlings; Reaz Vawda
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

3.  A new technique for minimal invasive complete spinal cord injury in minipigs.

Authors:  Elena E Foditsch; Gratian Miclaus; Irina Patras; Ioan Hutu; Karin Roider; Sophina Bauer; Günter Janetschek; Ludwig Aigner; Reinhold Zimmermann
Journal:  Acta Neurochir (Wien)       Date:  2018-01-12       Impact factor: 2.216

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.